Evidence map›Paper›PMID 42698634›Full record

ReviewBiosafety and health2026

Live-attenuated vaccines of human respiratory syncytial virus for infants and young children: Progress and prospects of an old yet promising platform.

Jiemei Yu, Yuanhui Fu, Yanpeng Zheng, Xianglei Peng, Jinsheng He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biosafety and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiemei YuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Yuanhui FuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Yanpeng ZhengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Xianglei PengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Jinsheng HeCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract illness (LRTI) in infants, young children, and the elderly. Although long-acting monoclonal antibodies, subunit, and messenger ribonucleic acid (mRNA) vaccines can protect vulnerable populations (infants < 6 months old and older adults)

Indexed as

Clinical studiesHuman respiratory syncytial virus (RSV)Intranasal vaccine for infants and young childrenLive-attenuated vaccine (LAV)Vaccine-associated enhanced respiratory disease (VAERD)

Identifiers

PMID42698634
PMCPMC13541641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.